MONTREAL, July 31 /PRNewswire/ -- Aegera Therapeutics Inc. is pleased to announce the dosing of the first patient in a fifth phase 1 and 2 clinical oncology study of AEG35156, a second generation antisense therapeutic targeting XIAP, a key member of the Inhibitor of Apoptosis protein family.
The study, made possible, in part, by funding from The Leukemia & Lymphoma Society, is entitled "A Phase 1-2, Multicenter, Open-Label Study of the X- Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma and Follicular Lymphoma." It is being conducted at the Princess Margaret Hospital (PMH) located in Toronto, Ontario, and is led by Principal Investigator Dr. Christine Chen, with co-Principal Investigators Dr. Aaron Schimmer and Dr. Joe Brandwein, all from the PMH's Department of Hematology and Oncology.
The primary objective of this study is to determine the recommended dose of AEG35156 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and follicular lymphoma (FL), and to determine the safety profile and response rate to AEG35156 in these patient populations.
"Preliminary evidence of activity in lymphoma was observed in phase 1 studies with AEG35156," stated Dr. Jacques Jolivet, Aegera's VP Clinical. "This clinical trial will specifically study the role played by XIAP knockdown in inducing antitumor activity in CLL, SLL and FL."
"Our clinical program around AEG35156 continues to expand and broaden
as we seek to move this therapeutic forward to approval," added Aegera's
President and Chief Executive Officer, Dr. Michael J. Berendt. "By adding
these lymphoma indications to AEG35156's ongoing phase 1 and 2 studies in
leukemia (AML), pancreatic, breast, and non-small cell lung cancer, we
continue to seek to position AEG35156 as an important therapeutic option
that could address important unme
|SOURCE Aegera Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved